VivoSeq
Oncology

Urinary Bladder Cancer

86

Pipeline Programs↗

5

Active Trials↗

44

Companies Involved↗

Urinary Bladder Cancer is a moderately active landscape with 86 programs across 44 companies. The most active players are GSK, Eisai, Kura Oncology, Inc.. 42 therapies are approved with 20 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 1Eisai logo

Eisai

1 program

Phase 1K

Kura Oncology, Inc.

1 program

Phase 2C

Coherus Oncology, Inc.

1 program

Phase 2Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

1 program

Phase 2S

Shanghai Pharmaceuticals Holding Co., Ltd

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

70 of 89 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody1315%Protein / enzyme33%Antibody–drug conjugate22%Vaccine11%

Small molecule leads; the ring shows all 89 classified programs, each share of the total. Modality classified for 99% of 92 pipeline programs.

Analysis

Trial Status

6

clinical trials

Active, not recruiting3 · 50%
Recruiting1 · 17%
Completed1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)
Recruiting·UUniversity of Thessaly·Phase 3·NCT04947059·180 enrolled
Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer
Active, not recruiting·—·Phase 3·NCT05822934·20 enrolled
Phase II Trial of Intravesical Gemcitabine + Docetaxel in Patients With Nonmuscle Invasive Bladder Cancer With or Without Prior Bacillus Calmette-Guérin Therapy
Active, not recruiting·UUniversity of Arizona·Phase 2·NCT05644041·31 enrolled
A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC)
Active, not recruiting·—·Phase 3·NCT05024773·130 enrolled
A Phase 2 Study to Assess Efficacy of Induction Enfortumab Vedotin Plus Pembrolizumab Using a Response-adapted Approach to Spare the Bladder: FIDELIO
Not yet recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT07663747·56 enrolled
Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer
Completed·NNational and Kapodistrian University of Athens·N/A·NCT05675176·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)